Table 3.
Between-gender differences combining HIGH and LOW group participants for self-reported measures, including baseline adjustment
| Baseline (n = 160) | Week 4 (n = 158) | Week 4-baseline (n = 158) | Week 16 (n = 150) | Week 16-baseline (n = 150) | |
|---|---|---|---|---|---|
| Self-rated mobility as good* | 1.2 (0.5 to 3.4), 0.690† | 1.0 (0.5 to 2.4), 0.940† | 1.0 (0.4 to 2.3), 0.999† | 0.5 (0.2 to 1.1), 0.082†∫ | 0.5 (0.2 to 1.1), 0.078†∫ |
| Self-rated strength as good* | 0.8 (0.2 to 2.4), 0.632† | 0.4 (0.1 to 1.3), 0.136† | 0.4 (0.1 to 1.4), 0.155† | 0.6 (0.3 to 1.5), 0.310†∫ | 0.7 (0.3 to 1.7), 0.387†∫ |
| Self-rated balance as good* | 0.9 (0.4 to 2.0), 0.718† | 1.0 (0.4 to 2.4), 0.940† | 1.0 (0.4 to 2.6), 0.953† | 0.8 (0.3 to 1.9), 0.611†∫ | 0.9 (0.4 to 2.0), 0.711†∫ |
| Self-rated pain as none or slight* | 0.8 (0.3 to 1.9), 0.602† | 0.7 (0.3 to 1.6), 0.450† | 0.8 (0.3 to 1.7), 0.505† | 1.0 (0.4 to 2.5), 0.920† | 1.1 (0.5 to 2.6), 0.887† |
| Self-rated health as worse* | 1.0 (0.4 to 2.1), 0.899 | 0.9 (0.4 to 2.0), 0.772§ | 0.9 (0.4 to 2.0), 0.785§ | 0.7 (0.3 to 1.9), 0.476∫ | 0.8 (0.3 to 2.1), 0.605∫ |
| Modified falls efficacy scale | 10.3 (-2.3 to 22.8), 0.109†‡ | 8.4 (-3.8 to 20.7), 0.174†§ | 3.7 (-7.3 to 14.6), 0.507†ǁ | 4.7 (-9.8 to 19.3), 0.520†∫ | -0.7 (-13.8 to 12.4), 0.916†** |
| EQ5D | 0.02 (-0.09 to 0.1), 0.765 | 0.04 (-0.07 to 0.2), 0.510 | 0.03 (-0.07 to 0.1), 0.535 | -0.03 (-0.2 to 0.09), 0.610†∫ | -0.04 (-0.2 to 0.08), 0.529†∫ |
Results as mean (95% CI), p unless *indicating results as odds ratio (CI 95%), p; †indicates men performed better than women; ‡n = 158; §n = 157; ǁn = 155; ∫n = 149; **n = 146.